Houston, TX12 Active Studies

Atrial Fibrillation Clinical Trials in Houston, TX

Find 12 actively recruiting atrial fibrillation clinical trials in Houston, TX. Connect with local research sites and explore new treatment options.

12
Active Trials
11
Sponsors
18,639
Enrolling

Recruiting Atrial Fibrillation Studies in Houston

About Atrial Fibrillation Clinical Trials in Houston

Atrial fibrillation (AFib) is the most common type of heart arrhythmia, causing an irregular and often rapid heartbeat. It significantly increases the risk of stroke, heart failure, and other complications. Treatment includes blood thinners, heart rate or rhythm control medications, and procedures like ablation.

There are currently 12 atrial fibrillation clinical trials recruiting participants in Houston, TX. These studies are seeking a combined 18,639 participants. Research is being sponsored by Regeneron Pharmaceuticals, Population Health Research Institute, Abbott Medical Devices and 8 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Atrial Fibrillation Clinical Trials in Houston — FAQ

Are there atrial fibrillation clinical trials in Houston?

Yes, there are 12 atrial fibrillation clinical trials currently recruiting in Houston, TX. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Houston?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Houston research site will contact you about next steps.

Are clinical trials in Houston free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Houston studies also compensate for your time and travel.

What atrial fibrillation treatments are being tested?

The 12 active trials in Houston are testing new therapies including novel drugs, biologics, and treatment approaches for atrial fibrillation.

Data updated September 7, 2026 from ClinicalTrials.gov